GlassScriptPhysician profile
Silvio Alan Del Castillo
NPI 1255405825
$5,458.03
in general payments reported to CMS, 2019-2025
40 companies · $731 in 2025
The $731 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $440 · 2021: $618 · 2022: $696 · 2023: $1,218 · 2024: $1,104 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050 · Travel and Lodging: $3.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.99 |
| Travel and Lodging | $3.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $813.66 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.98 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $555.81 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $474.52 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $406.05 | 2021-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $325.41 | 2021-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $310.90 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $248.11 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $211.74 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Amgen INC. | $195.02 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Pfizer INC. | $134.62 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.49 | 2020-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $92.16 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $90.92 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $85.11 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvio Del Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.